Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

被引:2
作者
Varadi, Melinda
Horvath, Orsolya
Modos, Orsolya
Fazekas, Tamas
Grunewald, Camilla M. [1 ,2 ]
Niegisch, Guenter [1 ,2 ]
Krafft, Ulrich [3 ]
Gruenwald, Viktor [3 ]
Hadaschik, Boris [3 ]
Olah, Csilla [3 ]
Maraz, Aniko [4 ]
Furka, Andrea [5 ,6 ]
Szucs, Miklos
Nyirady, Peter
Szarvas, Tibor [3 ]
机构
[1] Heinrich Heine Univ, Dept Urol, Fac Med, Dusseldorf, Germany
[2] Heinrich Heine Univ, Univ Hosp Duesseldorf, Dusseldorf, Germany
[3] Univ Duisburg Essen, Dept Urol, Hufelandstr 55, D-45147 Essen, Germany
[4] Univ Szeged, Dept Oncotherapy, Szeged, Hungary
[5] Univ Debrecen, Dept Oncol, Fac Med, Debrecen, Hungary
[6] Univ Miskolc, Dept Clin Radiol, Inst Pract Methodol & Diagnost, Fac Hlth Care, Miskolc, Hungary
关键词
CHEMOTHERAPY; CANCER; ATEZOLIZUMAB; MODEL;
D O I
10.1038/s41598-023-44103-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model.
引用
收藏
页数:11
相关论文
共 31 条
  • [21] Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean
    Powles, Tom
    van der Heijden, Michiel S.
    Balar, Arjun V.
    Necchi, Andrea
    Dawson, Nancy
    O'Donnell, Peter H.
    Balmanoukian, Ani
    Loriot, Yohann
    Srinivas, Sandy
    Retz, Margitta M.
    Grivas, Petros
    Joseph, Richard W.
    Galsky, Matthew D.
    Fleming, Mark T.
    Petrylak, Daniel P.
    Perez-Gracia, Jose Luis
    Burris, Howard A.
    Castellano, Daniel
    Canil, Christina
    Bellmunt, Joaquim
    Bajorin, Dean
    Nickles, Dorothee
    Bourgon, Richard
    Frampton, Garrett M.
    Cui, Na
    Mariathasan, Sanjeev
    Abidoye, Oyewale
    Fine, Gregg D.
    Dreicer, Robert
    [J]. LANCET, 2016, 387 (10031) : 1909 - 1920
  • [22] Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
    Ruiz-Banobre, J.
    Molina-Diaz, A.
    Fernandez-Calvo, O.
    Fernandez-Nunez, N.
    Medina-Colmenero, A.
    Santome, L.
    Lazaro-Quintela, M.
    Mateos-Gonzalez, M.
    Garcia-Cid, N.
    Lopez-Lopez, R.
    Vazquez, S.
    Anido-Herranz, U.
    [J]. ESMO OPEN, 2021, 6 (02)
  • [23] Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    Sharma, Padmanee
    Retz, Margitta
    Siefker-Radtke, Arlene
    Baron, Ari
    Necchi, Andrea
    Bedke, Jens
    Plimack, Elizabeth R.
    Vaena, Daniel
    Grimm, Marc-Oliver
    Bracarda, Sergio
    Arranz, Jose Angel
    Pal, Sumanta
    Ohyama, Chikara
    Saci, Abdel
    Qu, Xiaotao
    Lambert, Alexandre
    Krishnan, Suba
    Azrilevich, Alex
    Galsky, Matthew D.
    [J]. LANCET ONCOLOGY, 2017, 18 (03) : 312 - 322
  • [24] Real-World Evidence - What Is It and What Can It Tell Us?
    Sherman, Rachel E.
    Anderson, Steven A.
    Dal Pan, Gerald J.
    Gray, Gerry W.
    Gross, Thomas
    Hunter, Nina L.
    LaVange, Lisa
    Marinac-Dabic, Danica
    Marks, Peter W.
    Robb, Melissa A.
    Shuren, Jeffrey
    Temple, Robert
    Woodcock, Janet
    Yue, Lilly Q.
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (23) : 2293 - 2297
  • [25] PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
    Stenehjem, David D.
    Tran, Dao
    Nkrumah, Michael A.
    Gupta, Shilpa
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 5973 - 5989
  • [26] Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England
    Tan, Yen Yi
    Papez, Vaclav
    Chang, Wai Hoong
    Mueller, Stefanie H.
    Denaxas, Spiros
    Lai, Alvina G.
    [J]. LANCET HEALTHY LONGEVITY, 2022, 3 (10): : E674 - E689
  • [27] EMA and FDA prune the checkpoint inhibitor treatment landscape
    Teo, Min Yuen
    Rosenberg, Jonathan E.
    [J]. NATURE REVIEWS UROLOGY, 2018, 15 (10) : 595 - 597
  • [28] Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
    Tural, Deniz
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Artac, Mehmet
    Ozhan, Nail
    Akar, Emre
    Cakar, Burcu
    Kostek, Osman
    Ekenel, Meltem
    Erman, Mustafa
    Coskun, Hasan Senol
    Selcukbiricik, Fatih
    Keskin, Ozge
    Turkoz, Fatma Paksoy
    Oruc, Kerem
    Bayram, Selami
    Yglmaz, Ugur
    Bilgetekin, Irem
    Ygldgz, Birol
    Sendur, Mehmet Ali Nahit
    Paksoy, Nail
    Dirican, Ahmet
    Erdem, Dilek
    Selam, Meltem
    Tanrgverdi, Ozgur
    Paydas, Semra
    Urakcg, Zuhat
    Atag, Elif
    Guncan, Sabri
    Urun, Yuksel
    Alkan, Ali
    Kaya, Ali Osman
    Ozyukseler, Deniz Tataroglu
    Taskaynatan, Halil
    Ygldgrgm, Mustafa
    Sonmez, Muge
    Basoglu, Tugba
    Gunduz, Seyda
    Kglgckap, Saadettin
    [J]. EUROPEAN UROLOGY FOCUS, 2021, 7 (05): : 1061 - 1066
  • [29] Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration
    Vander Velde, Nancy
    Guerin, Annie
    Ionescu-Ittu, Raluca
    Shi, Sherry
    Wu, Eric Q.
    Lin, Shih-Wen
    Hsu, Ling-, I
    Saum, Kai-Uwe
    de Ducla, Sabine
    Wang, Jingjing
    Li, Shi
    Thastrom, AnnChristine
    Liu, Shuqian
    Shi, Lizheng
    Leppert, John T.
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (01): : 12 - 20
  • [30] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
    Vuky, Jacqueline
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean
    Hahn, Noah M.
    Savage, Mary J.
    Fang, Xiao
    Godwin, James Luke
    Frenkl, Tara L.
    Moreno, Blanca Homet
    de Wit, Ronald
    Plimack, Elizabeth R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +